Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Round-Up: Glenmark Recruits API Head From Mylan

Executive Summary

Glenmark chooses a head for its API unit, Lannett’s CFO retires, and Sterling Pharma Solutions names a leader in the US.

You may also be interested in...



Glenmark Invites Investment Into Its Independent APIs Unit

Bringing in a minority investor for its Glenmark Life Sciences raw materials unit and divesting non-core products are among the strategic priorities for Glenmark in its current financial year ending in March 2020.

Manufacturing Round-Up: Sterling Completes Expansion As Xellia Teams With Civica Rx

Sterling Pharma Solutions completes an expansion of its UK pilot plant facility, Aphena invests, Dr Reddy’s and Asymchem get nods from the FDA, Ampersand Capital Partners acquires Germany’s Vibalogics, and Xellia strikes a deal with Civica Rx.

Manufacturing Round-Up: Sterling Gains A US Site As Normon Invests €100m

Sterling Pharma Solutions has acquired a US facility and Olon has bought a plant from Sandoz, while Normon is investing €100m in manufacturing expansions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB140374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel